Company reports a 65% overall reduction in depressive symptoms one month after treatment cessation.
MindBio Therapeutics Corp. announced promising results June 20 from its Phase 2A clinical trials testing MB22001, a self-administered microdose of LSD, for depression treatment.
The company reported a 65% overall reduction in depressive symptoms one month after treatment cessation. The trial demonstrated safety, adherence and tolerance consistent with Phase 1 results.
MindBio is currently conducting two Phase 2B trials, fully funded through 2025, testing MB22001 for depression and cancer-related symptoms. A third Phase 2B trial for premenstrual syndrome and premenstrual dysphoric disorder has been approved.
The company’s approach differs from other psychedelic trials by using microdoses that patients can take at home, rather than larger doses administered in clinical settings.
Justin Hanka, CEO of MindBio, stated, “This data is another small step towards commercialization.”
MindBio Therapeutics is listed on the Canadian Securities Exchange under the symbol MBIO.